1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile
Journal of Medicinal Chemistry2006Vol. 49(24), pp. 7247–7251
Citations Over TimeTop 10% of 2006 papers
Daniele Fancelli, Jürgen Moll, Mario Varasi, Rodrigo Bravo, Roberta Artico, Daniela Berta, Simona Bindi, Alexander D. Cameron, Ilaria Candiani, Paolo Cappella, Patrizia Carpinelli, Walter Croci, Barbara Forte, Maria Laura Giorgini, Jan Klapwijk, Aurelio Marsiglio, Enrico Pesenti, Maurizio Rocchetti, Fulvia Roletto, D. Severino, Chiara Soncini, Paola Storici, R. Tonani, Paola Zugnoni, Paola Vianello
Abstract
The optimization of a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives toward the inhibition of Aurora kinases led to the identification of compound 9d. This is a potent inhibitor of Aurora kinases that also shows low nanomolar potency against additional anticancer kinase targets. Based on its high antiproliferative activity on different cancer cell lines, favorable chemico-physical and pharmacokinetic properties, and high efficacy in in vivo tumor models, compound 9d was ultimately selected for further development.
Related Papers
- → Validating Aurora B as an anti-cancer drug target(2006)283 cited
- → Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase(2005)114 cited
- → Clinical Experience with Aurora Kinase Inhibitors: A Review(2009)103 cited
- → Aurora A and B Kinases - Targets of Novel Anticancer Drugs(2010)16 cited
- → CDKN1A-mediated responsiveness ofMLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors(2013)9 cited